Moreover, combined survival analysis (Figure 3G,H) showed the worst prognosis for patients with TA-MUC1+ serous carcinoma in case of a high MDR1+ immune cell infiltrate (median PFS 25.80 vs. 39.60 months, p = 0.007, n = 81; median OS 27.84 vs. 50.64 months, p = 0.007, n = 81). The gene discussed is MUC1; the disease is serous adenocarcinoma.